» Articles » PMID: 35625840

Vascularization of Patient-Derived Tumoroid from Non-Small-Cell Lung Cancer and Its Microenvironment

Abstract

Patient-derived tumoroid (PDT) has been developed and used for anti-drug screening in the last decade. As compared to other existing drug screening models, a PDT-based in vitro 3D cell culture model could preserve the histological and mutational characteristics of their corresponding tumors and mimic the tumor microenvironment. However, few studies have been carried out to improve the microvascular network connecting the PDT and its surrounding microenvironment, knowing that poor tumor-selective drug transport and delivery is one of the major reasons for both the failure of anti-cancer drug screens and resistance in clinical treatment. In this study, we formed vascularized PDTs in six days using multiple cell types which maintain the histopathological features of the original cancer tissue. Furthermore, our results demonstrated a vascular network connecting PDT and its surrounding microenvironment. This fast and promising PDT model opens new perspectives for personalized medicine: this model could easily be used to test all therapeutic treatments and could be connected with a microfluidic device for more accurate drug screening.

Citing Articles

3D cell culture models in research: applications to lung cancer pharmacology.

Vella N, Fenech A, Petroni Magri V Front Pharmacol. 2024; 15:1438067.

PMID: 39376603 PMC: 11456561. DOI: 10.3389/fphar.2024.1438067.


Lung cancer organoids: models for preclinical research and precision medicine.

Liu Y, Zhou Y, Chen P Front Oncol. 2023; 13:1293441.

PMID: 37941550 PMC: 10628480. DOI: 10.3389/fonc.2023.1293441.


vascularized immunocompetent patient-derived model to test cancer therapies.

Le H, Deforges J, Hua G, Idoux-Gillet Y, Ponte C, Lindner V iScience. 2023; 26(10):108094.

PMID: 37860774 PMC: 10582498. DOI: 10.1016/j.isci.2023.108094.


Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer.

Nounsi A, Seitlinger J, Ponte C, Demiselle J, Idoux-Gillet Y, Pencreach E Biomedicines. 2023; 11(7).

PMID: 37509464 PMC: 10376341. DOI: 10.3390/biomedicines11071824.


Advances in the Lung Cancer Immunotherapy Approaches.

Padinharayil H, Alappat R, Joy L, Anilkumar K, Wilson C, George A Vaccines (Basel). 2022; 10(11).

PMID: 36423060 PMC: 9693102. DOI: 10.3390/vaccines10111963.


References
1.
Salgueiro L, Kummer S, Sonntag-Buck V, Weiss A, Schneider M, Krausslich H . Generation of Human Lung Organoid Cultures from Healthy and Tumor Tissue to Study Infectious Diseases. J Virol. 2022; 96(7):e0009822. PMC: 9006928. DOI: 10.1128/jvi.00098-22. View

2.
Fatehullah A, Tan S, Barker N . Organoids as an in vitro model of human development and disease. Nat Cell Biol. 2016; 18(3):246-54. DOI: 10.1038/ncb3312. View

3.
Hickman J, Graeser R, De Hoogt R, Vidic S, Brito C, Gutekunst M . Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo. Biotechnol J. 2014; 9(9):1115-28. DOI: 10.1002/biot.201300492. View

4.
Li X, Valadez A, Zuo P, Nie Z . Microfluidic 3D cell culture: potential application for tissue-based bioassays. Bioanalysis. 2012; 4(12):1509-25. PMC: 3909686. DOI: 10.4155/bio.12.133. View

5.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View